Lupin launches Fluocinonide Ointment USP 0.05%
Deepthi | Myequity news | Date : 28-03-2019 16:52:00 IST
Pharma major Lupin launched Fluocinonide Ointment USP, 0.05%, having received an approval from the United States Food and Drug Administration (FDA) earlier.
Lupin’s Fluocinonide Ointment USP, 0.05%, is the generic version of County Line Pharmaceuticals LLC’s Lidex® Ointment 0.05%. It is indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid- responsive dermatoses.
Fluocinonide Ointment USP, 0.05% (RLD: Lidex) had annual sales of approximately USD 15 million in the U.S (IQVIA MAT January 2019).
About Lupin Limited
Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally. The Company is a significant player in the Cardiovascular, Diabetology, Asthma, Pediatric, CNS, GI, Anti-Infective and NSAID space and holds global leadership position in the Anti-TB segment.